CYP2C9 and CYP2C19 loss-of-function polymorphisms were present to a similar extent in patients without and with hyperuricemia (CYP2C9: 33 (16.4%) vs. 8 (10.4%) patients; CYP2C19: 58 (28.9%) vs. 28 (36.4%) patients; both p > 0.2). This evidence concerns the gene CYP2C9 and hyperuricemia.